Dense Hyperthermic Intraperitoneal Chemotherapy with Cisplatin in Patients with Stage III Serous Epithelial Ovarian Cancer: A Retrospective Study

Xiaoli He

Henan Provincial People's Hospital

Li Wei

Henan Provincial People's Hospital

Rui Li

Henan Provincial People's Hospital

Shuang Jing

Henan Provincial People's Hospital

Linlin Jia

Henan Provincial People's Hospital

Danwei Ji

Henan Provincial People's Hospital

Yali Li

Henan Provincial People's Hospital

Yue Wang

Henan Provincial People's Hospital

Yongxia Zhu (✉ zhuyongxia0409@163.com)

Sichuan University <https://orcid.org/0000-0002-5977-9579>

Research article

Keywords: Dense hyperthermic intraperitoneal chemotherapy, Serous epithelial ovarian cancer, Survival, Interval debulking surgery

Posted Date: October 22nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-179783/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: To investigate the efficacy and safety of interval debulking surgery (IDS) combined with dense hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in Chinese patients with FIGO stage III serous epithelial ovarian cancer (EOC).

Methods: This retrospective single-center study reviewed the demographic and clinical data of 197 patients with primary FIGO stage III serous EOC who were treated with IDS with (n=121) or without (n=76, control group) dense HIPEC between January 2012 and April 2017. The co-primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoint was the occurrence of adverse events.

Results: The median PFS was 24 months in the IDS plus dense HIPEC group, whereas it was 19 months in the IDS alone group (hazard ratio [HR] 0.46, 95% confidence interval [CI]: 0.33-0.65, $p=0.000$). The median OS in patients treated with IDS plus dense HIPEC (51 months) was significantly longer than that in patients treated with IDS alone (40 months, HR 0.52, 95% CI: 0.35-0.78, $p=0.001$). The demographic and preoperative clinical characteristics of these two groups were comparable ($p>0.05$). In the IDS alone group, no adverse events were recorded in 42 (55.3%) of the 76 patients, and 14 (18.4%) patients were reported to have grade III/IV adverse events. In the IDS plus dense HIPEC group, no adverse events were recorded in 55 (45.5%) of the 121 patients, and 23 (19.0%) patients were reported to have grade III/IV adverse events. No postoperative deaths occurred within 30 days in either group and neither did severe fatal complications in the IDS plus dense HIPEC group.

Conclusions: IDS plus dense HIPEC with cisplatin in Chinese patients with FIGO stage III serous EOC is associated with improved survival and is reasonably well tolerated by patients.

Background

Epithelial ovarian cancer (EOC) has the highest mortality rate among all gynecological tumors worldwide, causing nearly 22,500 deaths in China in 2015 and 14,335 deaths in the United States in 2018 [1, 2]. The most effective treatment for advanced EOC remains primary cytoreductive surgery (CRS) followed by intravenous chemotherapy with carboplatin and paclitaxel [3, 4]. In patients where complete primary cytoreduction is impossible, interval debulking surgery (IDS) can be performed after 2–4 cycles of neoadjuvant chemotherapy (NACT) [5–7]. Peritoneum is the primary site of metastasis of tumor cells from the ovary in advanced EOC patients [8, 9]. Therefore, intraperitoneal chemotherapy is used to improve outcomes and minimize tumor dissemination and implantation [10, 11].

Hyperthermic intraperitoneal chemotherapy (HIPEC) is delivered under hyperthermic conditions and used to increase chemotherapy penetration into peritoneal tumors, including advanced EOC [12]. Randomized trials, meta-analyses, and retrospective studies have all shown that HIPEC is feasible and associated with prolonged ovarian cancer survival rates [13–15]. Some studies have demonstrated that despite the promise of HIPEC, HIPEC did not improve patient survival data compared with therapy without HIPEC [3,

14, 16]. Interestingly, in a meta-analysis of patients with primary EOC, Huo et al. showed that HIPEC combined with CRS was associated with a significantly improved 2-, 3-, 4-, 5-, and 8-year OS compared with CRS alone [17].

In those studies, different drug and dose ranges of HIPEC were used, which resulted in dissimilar survival times. In some studies, HIPEC was administered only after optimal cytoreductive surgery using cisplatin or a combination of doxorubicin, paclitaxel, or mitomycin C [8, 18–20]. In other studies, patients received HIPEC with different doses of cisplatin [14, 21–23]. Numerous investigations conducted to assess dose dense chemotherapy have shown clinical benefits. For instance, Ba M, et al. showed that HIPEC procedures with three sessions were performed on the first, third, and fifth days after CRS was comparable to other HIPEC procedures [22]. Therefore, we referenced the procedure that have three sessions and defined them as Dense HIPEC with cisplatin.

In this single-center study, we sought to retrospectively analyze the role of IDS combined with dense HIPEC with cisplatin in patients with primary FIGO stage III serous EOC after NACT compared with IDS alone.

Methods

Patients

This retrospective study was approved by the Human Ethics Committee of Henan Provincial People's Hospital in China, and written informed consent was obtained from each patient prior to all treatment procedures. All patients in this study were diagnosed with FIGO stage III high-grade serous ovarian cancer, which based on surgical findings and histopathological results, between January 1, 2012 and April 31, 2017 at the Department of Gynecology, Henan Provincial People's Hospital. Staging was done based on the 1988 International FIGO staging system between January 1, 2012 and December 31, 2012, the 2013 International FIGO staging system between January 1, 2013 and December 31, 2013, and the 2014 International FIGO staging system between January 1, 2014 and April 31, 2017 [24]. The medical records of all patients were reviewed, and all patients were followed up until March 31, 2020.

All patients who demonstrated an Eastern Cooperative Oncology Group (ECOG) score 0–1 [25, 26] in our study underwent 2–4 cycles of NACT with a combination of carboplatin (area under the curve of 5–6 mg per milliliter per minute, AUC 5–6) and paclitaxel (175 mg per square meter of body-surface area, 175 mg/m²). After NACT, IDS was performed using peritonectomy. Complete cytoreductive surgery was defined as surgery that resulted in no visible disease (residual disease classification, R0), optimal cytoreductive surgery as surgery that resulted in the presence of one or more residual tumors measuring ≤ 1 cm in diameter (R1), and incomplete cytoreductive surgery as surgery that resulted in the presence of one or more residual lesions measuring > 1 cm in diameter (R2) [27]. In this study, regardless of whether satisfactory tumor cell reduction is achieved after IDS (single or more residual lesions ≤ 1 cm), HIPEC was performed with the consent of patients and family members. According to the patient's request and a

multidisciplinary discussion among general surgeons, gynecologists, and physicians, patients were divided into two groups: an IDS plus dense HIPEC group and an IDS alone control group.

Inclusion and exclusion criteria

The inclusion criteria were as follows. (1) Patients aged ≥ 18 years. (2) Patients that underwent pretreatment and preoperative evaluation with computed tomography (CT) or magnetic resonance imaging (MRI), pelvic ultrasound, and had tumor markers (including cancer antigen 125 [CA125] and human epididymis protein 4 [HE4]) as well as routine blood tests. (3) A pathologic diagnosis confirmed by ascites cytology or biopsy pathology. (4) Patients diagnosed with FIGO stage III serous EOC (high-grade serous ovarian cancer). (5) Patients with normal blood counts, and adequate renal function. (6) Patients with an ECOG performance status of 0–1.

The exclusion criteria were as follows. (1) Recurrent peritoneal ovarian cancer patients. (2) Patients with previous primary cytoreductive surgery. (3) Patients with the presence of extra-abdominal metastasis. (4) Patients that treated with bevacizumab or poly ADP-ribose polymerase inhibitors. (5) Patients that with poor general health, renal insufficiency, heart failure, or the existence of a lesion in the central nervous system.

IDS plus dense HIPEC group

After the IDS procedure, dense HIPEC was administered using a custom-developed high-precision body cavity hyperthermic perfusion treatment system (BR-TRG-II, Bright Medical Technology Co., Ltd., Guangzhou, China) through closed procedures [22]. All patients underwent three sessions of HIPEC, and each session was performed in the general ward on the first, third, and fifth days after surgery with 60 min of cisplatin (60 mg/m^2).

In brief, after cytoreductive surgery, four perfusion chemotherapy catheters with multiple side holes were placed intra-abdominally; one was placed beneath each hemidiaphragm and two were placed in the pelvis. The abdomen was filled with saline that circulated continuously using the HIPEC device. By circulation of the heated saline, an intra-abdominal temperature of $42\text{--}43^\circ\text{C}$ was maintained. Cisplatin (60 mg/m^2) was perfused in equal amounts during each 60 min HIPEC session with a $450\text{--}600 \text{ mL/min}$ flow rate. The total perfusion volume was $3,500\text{--}4,500 \text{ mL}$, which was adjusted such that the entire abdomen was exposed to the perfusate. Four abdominal drains were closed during the intraperitoneal intraoperative chemotherapy and opened after 24 h, and all the perfusion liquid was drained prior to starting the next session. Four catheters were removed two days after the final HIPEC session. During HIPEC performed in the general ward, patients were attended by a dedicated therapist and monitored with electrocardiograph (ECG) monitoring. Meanwhile, the intervention treatment comprising dezocine and diazepam was administered to the patients. All patients received additional 3–4 cycles of systemic chemotherapy (paclitaxel 175 mg/m^2 plus carboplatin AUC 5–6) two weeks after the final HIPEC treatment. Before every HIPEC session, bone marrow, renal and hepatic function, parameters of blood electrolytes, and blood coagulation were examined.

IDS alone control group

We retrospectively selected FIGO III serous ovarian cancer patients who underwent 2–4 cycles of NACT (paclitaxel 175 mg/m² plus carboplatin AUC 5–6) followed by IDS. After surgery, 3–4 cycles of intravenous paclitaxel (175 mg/m²) and carboplatin (AUC 5–6) were administered every 21 days.

Study variables

The following information was reviewed and collected. Patient demographics, medical history, tumor markers, pathologic characteristics, chemotherapy regime including the dose, surgical procedures, tumor debulking status according to the visible residual disease classification [28], the pre- and post-HIPEC lab values (absolute neutrophil count, platelets, hematocrit, and hemoglobin), and HIPEC techniques and drugs, patient adverse events, length of hospital stay, and the cost of hospital data.

Follow-up

During follow-up after the completion of chemotherapy, physical examinations and measurements of CA125 and HE4 levels were performed every three months for two years and then every six months until the five-year point. CT or MRI was performed at least 1, 6, 12, and 24 months after the last cycle of chemotherapy.

The co-primary endpoints of this study were the survival curves for progression-free survival (PFS) and OS. Clinical, radiologic, and CA125 progression after the initial induction chemotherapy and time to normalization were identified as variables when assessing PFS. OS was defined as the time from the date of initiation of NACT to the date of death from any cause or final follow-up. Safety assessments were performed according to the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for adverse events (PRO-CTCAE) [29].

Statistical analyses

All statistical analyses were performed using SPSS statistical software (version 24.0 for Windows, IBM Corp., Armonk, NY, USA). The initial data analysis was conducted with a descriptive statistical approach. We used the Mann-Whitney U test for continuous variables and the χ^2 test for categorical variables. Survival analysis was performed using the Kaplan-Meier approach and the median follow-up was calculated using the reverse Kaplan-Meier approach. Hazard ratios (HRs) were estimated using a Cox proportional hazard model with a 95% Wald confidence interval (95% CI). All *p* values were two-sided with the level of significance set at *p* < 0.05.

Results

Patient demographics and clinical characteristics

A total of 197 FIGO stage III serous ovarian cancer patients (high-grade serous ovarian cancer) were reviewed, of whom 121 underwent IDS plus dense HIPEC (IDS plus dense HIPEC group) and 76 underwent IDS (IDS alone control group). There were no differences between the two groups in terms of patient age

($p = 0.337$) or body mass index (BMI; $p = 0.277$). Optimal cytoreductive surgery (R0 + R1) was achieved in 113 (93.4%) patients in the IDS plus dense HIPEC group and 70 (92.1%) patients in the IDS alone control group ($p = 0.734$). Although there were no differences in patient age ($p = 0.337$), the median duration of hospitalization after surgery was 8.91 (SD = 1.89) days in the IDS plus dense HIPEC group, which was longer than 8.07 (SD = 1.80) days in the IDS alone group ($p = 0.001$). In the IDS plus dense HIPEC group, patients were treated with a mean of 2.95 (SD = 0.62) cycles of NACT compared with 2.86 (SD = 0.60) cycles in the IDS alone group ($p = 0.442$). The individual surgery groups' demographic and clinical characteristics are described in Table 1.

Table 1
Demographic and clinical characteristics of patient between groups

Variable	IDS + HIPEC (n = 121)	IDS alone (n = 76)	p-value
Demographic mean (SD)			
Age	58.38 (10.89)	55.20 (10.87)	0.337 ^a
BMI (kg/m ²) (SD)	26.77 (2.78)	26.65 (2.40)	0.277 ^a
Neo-adjuvant chemotherapy cycles, n (%)			0.442 ^b
Two cycles	28 (23.1)	20 (26.3)	
Three cycles	74 (61.2)	47 (61.8)	
Four cycles	19 (15.7)	9 (11.8)	
Cyto-reductive surgery, n (%)			0.734 ^b
Optimal (R0 + R1)	113 (93.4)	70 (92.1)	
Sub-optimal (residual disease > 1 cm)	8 (6.6)	6 (7.9)	
Bowel resection, n (%)			0.523 ^b
No bowel resection performed	101 (83.5)	66 (86.8)	
Bowel resection performed	20 (16.5)	10 (13.2)	
Mean duration of hospitalization-days (SD) after surgery	8.91 (1.89)	8.07 (1.80)	0.001 ^a
Median time to postoperative systemic treatment with chemotherapy (SD)	22 (2.37)	15 (1.87)	0.001 ^a
Performance status (ECOG), n (%)			0.980 ^b
0	38 (31.4)	24 (31.6)	
1	83 (68.6)	52 (68.4)	
TC chemotherapy cycles after IDS (%)			0.015 ^b
3 cycles	6 (5.0)	5 (6.6)	
4 cycles	58 (47.9)	49 (64.5)	
5 cycles	57 (47.1)	22 (28.9)	

^aAnalysed using an Independent-Samples t-test; ^bAnalysed using the Mann-Whitney U test. ECOG: Eastern collaborative oncology group. TC: Paclitaxel and carboplatin.

Variable	IDS + HIPEC (n = 121)	IDS alone (n = 76)	<i>p</i> -value
Total of TC cycles (SD)	6.73 (0.53)	6.48 (0.66)	0.047 ^b
^a Analysed using an Independent-Samples t-test; ^b Analysed using the Mann-Whitney U test. ECOG: Eastern collaborative oncology group. TC: Paclitaxel and carboplatin.			

PFS and OS

The median follow-up was 46 and 38 months in the IDS plus dense HIPEC and IDS alone group, respectively. In the IDS plus dense HIPEC group, the median PFS was 24 (95% CI: 21.38–26.62) months compared with 19 (95% CI: 17.81–20.19) months in the IDS alone group ($p = 0.000$), suggesting that the IDS plus dense HIPEC group experienced a significantly longer PFS than the IDS alone group (Fig. 1). Of the 197 patients, 142 patients (72.1% of the recurrences) were detected based on imaging and 55 patients (27.9%) were detected based on an increase in CA125 levels alone (more than 35 U/mL). Overall, 69 of the 121 patients (52.02%) in the IDS plus dense HIPEC group and 55 of the 76 patients (72.37%) in the IDS alone group died during the follow-up period. The median OS was 51 (95% CI: 42.73–59.27) months in the IDS plus dense HIPEC group and 40 (95% CI: 37.59–42.41) months in the IDS group ($p = 0.001$, Fig. 2). Significant differences were observed between the groups in both the median PFS (HR 0.46, 95% CI: 0.33–0.65, $p = 0.000$) and median OS (HR 0.52, 95% CI: 0.35–0.78, $p = 0.001$).

Adverse events due to HIPEC

Patients treated with IDS plus dense HIPEC received a mean of 4.4 (SD = 0.59) cycles of carboplatin and paclitaxel chemotherapy after a median duration of 22 days of postoperative systemic treatment with chemotherapy. Patients treated with IDS alone underwent a mean of 4.2 (SD = 0.56) cycles after a median duration of 15 days of postoperative systemic treatment with chemotherapy ($p = 0.000$). In the IDS plus HIPEC group, a total of seven patients could not complete three sessions of HIPEC, implying they only underwent two sessions of HIPEC. Two patients developed fever and had a body temperature as high as 39°C for three days, and four patients had intestinal obstruction symptoms after hyperthermic perfusion on both sides. In one patient, the third session of HIPEC was terminated because of intestinal anastomosis bleeding.

In the IDS plus HIPEC group, no adverse events were recorded in 55 (45.5%) of the 121 patients in the group, and 23 (19.0%) of the 121 patients were reported to have grade III or IV adverse events. Conversely, in the IDS alone group, no adverse events were recorded for 42 (55.3%) of the 76 patients, and 14 (18.4%) were reported to have grade III-IV adverse events. The main adverse events observed in this study are summarized in Table 2. The most common grade I-II adverse event observed in this study was an electrolyte disturbance, and the most common grade III-IV adverse event was ileus. All HIPEC procedures were performed in the general ward and not in the intensive care unit (ICU). No deaths occurred within the

first 30 days postoperatively in the two groups of patients and neither did severe fatal complications in the IDS plus dense HIPEC group.

Table 2

Adverse events for the ovarian cancer patients treated with IDS plus HIPEC (n = 121) and IDS alone (n = 76)

Adverse events n (%)	Grade I or II		Grade III or IV	
	IDS + HIPEC	IDS alone	IDS + HIPEC	IDS alone
Haematology				
Leucocytopenia	21 (17.4)	2 (2.6)	0	0
Thrombocytopenia	9 (7.4)	0	0	0
Anemia	30 (24.8)	18 (23.7)	1 (0.8)	2 (2.6)
Electrolyte disturbance*	38 (31.4)	20 (26.3)	4 (3.3)	2 (2.6)
Thromboembolism	10 (8.3)	5 (6.6)	3 (2.5)	2 (2.6)
Nausea	27 (22.3)	15 (19.7)	0	0
Emesis	16 (13.2)	9 (11.8)	0	0
Nephrotoxicity	5 (4.1)	0	0	0
Abdominal pain	26 (21.5)	13 (17.1)	2 (1.7)	0
Ileus	6 (5.0)	2 (2.6)	10 (8.3)	5 (6.6)
Anastomotic hemorrhage	4 (3.3)	3 (3.9)	2 (1.7)	0
Infection	15 (12.4)	11 (14.5)	3 (2.5)	3 (3.9)
Electrolyte disturbances included hyponatremia, hypochloridemia, hypokalemia, hypocalcemia, hypomagnesemia and hypophosphatemia. Infection included lung infection, urinary tract infection, urethral infection, stoma site infection, sepsis, bacteremia, abdominal infection.				

Discussion

In most cases of advanced ovarian cancer, peritoneal metastasis is the primary site of spread and cause of treatment failure [9]. Several randomized clinical trials have shown that postoperative intraperitoneal and intravenous chemotherapy improved survival in patients with optimally resected stage IIIC ovarian cancer compared with intravenous chemotherapy alone [26, 30–32]. Although the survival benefits of intraperitoneal chemotherapy have been reported in a previous Gynecologic Oncology Group study [31], the toxicity and significantly high incidence of side effects have prevented this treatment from being widely adopted in clinical practice [12, 26]. In recent years, the application of HIPEC to ovarian cancer has garnered interest because of its advantages over standard intraperitoneal chemotherapy [12].

Nevertheless, the therapeutic of HIPEC in ovarian cancer has been controversial. Some studies have demonstrated that HIPEC does not improve OS compared with therapy without HIPEC [13]. However, an increasing number of studies have demonstrated that the addition of HIPEC significantly improves the prognosis of ovarian cancer [1, 22, 33–35], especially in randomized controlled trials [14, 16, 36]. The drug and dose range of HIPEC are important considerations that can affect survival times. In some studies, HIPEC was performed only after optimal cytoreductive surgery, either as an open procedure or a closed system, which used cisplatin or a combination of doxorubicin, paclitaxel, or mitomycin C [8, 18–20]. In other studies, patients underwent HIPEC with different doses of cisplatin [14, 22, 23]. In the study by Antonio et al., patients were treated with HIPEC and paclitaxel alone [21]. Hence, several investigations have shown that dose dense chemotherapy provides clinical benefits. Therefore, this study focused on the feasibility of dense HIPEC, which involves increasing the rate of chemotherapy with three sessions of HIPEC, in FIGO stage III serous EOC.

In the present study, the median PFS was 24 months in the IDS plus dense HIPEC group, which was significantly better than the 19 months observed in the IDS alone control group, suggesting the feasibility of dense HIPEC in patients with FIGO stage III serous EOC. Two groups of patients in this study received similar preoperative treatment and had the same disease stage and pathological type. No significant differences in cytoreductive surgery, pathological grade, or the total number of cycles of systematic intravenous chemotherapy existed between the two groups. Mendivil et al. reported improved PFS with HIPEC compared with intravenous chemotherapy (25.1 months versus 20.0 months, respectively; $p = 0.024$) [13], which corroborates the results of this study. Similarly, a randomized, controlled, open-label trial also documented an increased PFS (14.2 months versus 10.7 months) in cohorts treated with HIPEC chemotherapy [14].

Although previous studies reported favorable PFS results, OS benefits have conventionally been considered as the most dependable endpoint in assessing cancer-related treatments. In a multicenter, open-label, phase 3 trial [14] 245 patients who received NACT were randomly assigned to undergo interval cytoreductive surgery either with or without HIPEC with cisplatin (100 mg/m^2). A significant improvement in OS was seen: 45.7 months versus 33.9 months in the surgery plus HIPEC and surgery alone group, respectively. Notably, our results showing a median OS of 51.0 months for the IDS plus dense HIPEC group versus 40.0 months for the IDS alone group. Nevertheless, a recent retrospective case-control study of 56 patients treated for primary advanced ovarian cancer who underwent interval surgery with or without HIPEC demonstrated that although OS was better in the case group than in the control group ($p = 0.048$), PFS was not significantly different (13.2 months versus 13.9 months, $p = 0.454$) [8]. Conversely, another retrospective case-control study showed that PFS was significantly longer with HIPEC than without, but no OS advantages were identified. The differences in these results may have several explanations. First, follow-up differed in the two studies, and a shorter duration was inherent to the HIPEC group [13]. Second, the studies were retrospectively evaluated, and selection bias may have influenced the outcomes [13]. Third, a relatively small number of patients were included to obtain the results. Last,

the rate of the peritoneal metastasis differed, which is a critical determinant of survival in advanced ovarian cancer [8].

Unsurprisingly, we observed a reasonable toxicity profile in the patients receiving dense HIPEC. No grade IV adverse events were recorded in any of the 121 patients, and no adverse events were recorded in 55 (45.5%) patients, however, 43 patients developed grade II nausea during the three sessions of HIPEC. Notably, we did not observe any grade III-IV leukocytopenia, thrombocytopenia, or renal failure. Similarly, several retrospective studies did not report any evidence of grade III-IV toxicity in their experience of treating advanced ovarian cancer patients with HIPEC [13, 37].

To the best of our knowledge, HIPEC as a single treatment has only been administered at the end of cytoreductive surgery in the operating room or the ICU [8, 13, 14, 22], thus increasing not only patient safety and comfort but also medical costs [38]. However, in our center, dense HIPEC is delivered with cisplatin after cytoreductive surgery in the general ward, and no adverse events were found to be associated with this. Furthermore, the patient tolerability was excellent. The median time of postoperative systemic treatment with chemotherapy was 22 days, which was significantly lower than the 33–49 days reported in previous studies [8, 14].

In addition, specific pathologic subtypes affect the prognosis of advanced ovarian cancer. To reduce the impact of pathological type and disease stage on survival in the present study, we only included FIGO stage III high-grade serous EOC patients. Several limitations should be considered in this study. First, the retrospective nature of our analysis reduced our ability to draw reliable conclusions. Second, although NACT is increasingly used as the primary treatment for advanced ovarian cancer [39], patients who undergo primary debulking surgery have a significant survival benefit compared with those who undergo NACT. Third, this study showed that significant benefits in OS and PFS were associated with dense HIPEC, however, multivariate analyses were not performed to elucidate the risk factors of prognosis nor evaluate the impact of optimal cytoreductive surgery, CA125 level, age, and other variables. In a retrospective multicenter study of 78 patients by Le Saux, et al., the univariate analysis demonstrated that age ≥ 50 years, peritoneal cancer index (PCI) ≤ 8 , and CA125 levels < 100 were significantly associated with long-term survival in patients with EOC following cytoreductive surgery and HIPEC [40]. However, our data were limited to optimal or suboptimal cytoreductive surgery [27], and it may have been preferable to further stratify the surgery categories into complete (R0), optimal < 1 cm (R1), and suboptimal (R2) groups [31].

At present, there are many ongoing randomized Phase 2 and 3 trials involving primary and recurrent disease as well as patients receiving NACT [41]. Many of these trials intend to assess the impact of adding HIPEC to cytoreductive surgery on PFS and OS [41] as well as on morbidity, quality of life, and pharmacokinetics [42]. However, to the best of our knowledge, few randomized controlled clinical trials of dense HIPEC training and administration with the agents and protocols used in our study are ongoing.

Conclusions

This retrospective study of FIGO stage III serous EOC patients indicates that IDS plus dense HIPEC results in longer survival than IDS alone, and this treatment is reasonably well tolerated by patients. Future trials investigating the efficacy and safety of dense HIPEC plus debulking surgery in a similar setting are required.

Abbreviations

IDS: Interval debulking surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; EOC: Epithelial ovarian cancer; PFS: Progression-free survival; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; CRS: Cytoreductive surgery; NACT: Neoadjuvant chemotherapy; ECOG: Eastern cooperative oncology group; CT: Computed tomography; MRI: Magnetic resonance imaging; CA125: Cancer antigen 125; HE4: Human epididymis protein 4; ECG: Electrocardiograph; BMI: Body mass index; ICU: Intensive care unit; PCI: Peritoneal cancer index; TC: Paclitaxel and carboplatin.

Declarations

Ethics approval and consent to participate

This retrospective study was approved by the Human Ethics Committee of Henan Provincial People's Hospital in China, and written informed consent was obtained from each patient prior to all treatment procedures. Patients were informed that the resected specimens were stored by the hospital and potentially used for scientific research, and that privacy would be maintained.

Consent for publish

Not applicable.

Availability of data and materials

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no conflict of interest.

Funding

This work was supported by the Health Commission of Henan Province: Hyperthermic intraperitoneal chemotherapy in borderline mucous tumor under Grant [number 2018020423]. None of the funding agencies had a role in designing the study, writing the manuscript, nor the collection, analysis, and interpretation of data.

Authors' contributions

All authors contributed to the study conception and design. *XH*: planning and study design, study execution, and writing-initial draft. *LW* and *YZ*: Statistical analysis/interpretation, and writing-final revision. *RL*: Planning and study design; *SJ*, *LJ*, *DJ* and *YL*: Data collection and study execution. *YW*: Writing-final revision. All authors have read and approve the final version.

Acknowledgments

The authors thank all the patients and their family members for their interest and cooperation in the study.

Authors' information

¹Department of Gynecology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University. No.7, Weiwu Road, Jinshui District, Zhengzhou, 450003, China. ²Department of Gynecology and Obstetrics, Taikang Xian People's Hospital. No. 469, Jianshe Road, Taikang county, Zhoukou, 461400, China

References

1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(4):284–96.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *Cancer J Clin*. 2016;66(2):115–32.
3. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. *Gynecol Oncol*. 2010;118(3):262–7.
4. Marth C, Hiebl S, Oberaigner W, Winter R, Leodolter S, Sevela P. Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology. *Int J Gynecol Cancer*. 2009;19(1):94–102.
5. Vergote IB, Van Nieuwenhuysen E, Vanderstichele A. How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2016;34(32):3827–8.
6. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med*. 2010;363(10):943–53.
7. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. *Gynecol Oncol*. 2016;143(1):3–15.

8. Ceresoli M, Verrengia A, Montori G, Busci L, Coccolini F, Ansaloni L, Frigerio L. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study. *J Gynecol Oncol*. 2018;29(3):e53.
9. Friedrich M, Zinn W, Kolnsberg L, Kraft C, Kuhn W. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer: Evaluation of Side Effects in a Single Institution Cohort. *Anticancer research*. 2020;40(3):1481–6.
10. Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, Bertoli P, Busci LM, Lotti M, Cambria F, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. *Br J Cancer*. 2015;112(2):306–12.
11. Coccolini F, Acocella F, Morosi L, Brizzola S, Ghiringhelli M, Ceresoli M, Davoli E, Ansaloni L, D'Incalci M, Zucchetti M. High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation. *Pharm Res*. 2017;34(6):1180–6.
12. Riggs MJ, Pandalai PK, Kim J, Dietrich CS. **Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.** *Diagnostics (Basel)* 2020, 10(1).
13. Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Lopez KL, Goldstein BH. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. *Cancer Chemother Pharmacol*. 2017;80(2):405–10.
14. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh I, van der Velden J, Arts HJ, Massuger L, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. *N Engl J Med*. 2018;378(3):230–40.
15. Zhang G, Zhu Y, Liu C, Chao G, Cui R, Zhang Z. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis. *J Ovarian Res*. 2019;12(1):33.
16. Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, Bereder JM, Quenet F, Meeus P, Marchal F, et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIOVAC study. *Eur J Surg Oncol*. 2010;36(6):589–93.
17. Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. *Eur J Surg Oncol*. 2015;41(12):1578–89.
18. Cascales Campos PA, Gil Martinez J, Galindo Fernandez PJ, Gil Gomez E, Martinez Frutos IM, Parrilla Paricio P. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. *Eur J Surg Oncol*. 2011;37(6):543–8.
19. Delotte J, Arias T, Guerin O, Boulahssass R, Bereder I, Bongain A, Benchimol D, Bereder JM. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly

- women. *Acta Obstet Gynecol Scand*. 2015;94(4):435–9.
20. Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. *J Surg Oncol*. 2014;110(6):661–5.
 21. Antonio CCP, Francisco-Cristobal MC, Alida GG, Susana SG, Israel M, Rafael M, David PV, Pedro V, Fernando P, Elena G, et al: **Upfront cytoreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer**. *Clin Exp Metastasis* 2019.
 22. Ba M, Long H, Zhang X, Tang Y, Wu Y, Yu F, Wang S, Cui S. Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites. *J Cancer Res Clin Oncol*. 2014;140(9):1497–506.
 23. Deraco M, Kusamura S, Virzi S, Puccio F, Macri A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. *Gynecol Oncol*. 2011;122(2):215–20.
 24. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. *Gynecol Oncol*. 2014;133(3):401–4.
 25. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5(6):649–55.
 26. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2007;25(4):437–43.
 27. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC). *Gynecol Oncol*. 2006;103(2):559–64.
 28. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E: **2010 Gynecologic Cancer InterGroup (GCIg) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference**. *Int J Gynecol Cancer* 2011, **21**(4):750–755.
 29. Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, Onaya H, Endo M, Sone M, Arai Y: **[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]**. *Gan To Kagaku Ryoho* 2009, **36**(13):2495–2501.
 30. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology

- Group, and Eastern Cooperative Oncology Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001;19(4):1001–7.
31. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med*. 2006;354(1):34–43.
 32. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2015;33(13):1460–6.
 33. Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, Turco LC, Piovano E, Scambia G: **Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.** *Gynecologic oncology* 2012, **127**(3):502–505.
 34. Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. *J Surg Oncol*. 2010;101(2):149–55.
 35. Rettenmaier MA, Mendivil AA, Abaid LN, Brown lii JV, Wilcox AM, Goldstein BH. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. *Int J Hyperthermia*. 2015;31(1):8–14.
 36. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. *Ann Surg Oncol*. 2015;22(5):1570–5.
 37. Dharmadhikari N, Shah R, Jagannath P. Initial experience with hyperthermic intra peritoneal chemotherapy and cytoreductivesurgery. *Indian J Cancer*. 2014;51(2):189–92.
 38. Lim SL, Havrilesky LJ, Habib AS, Secord AA. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. *Gynecol Oncol*. 2019;153(2):376–80.
 39. Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. *Gynecol Oncol*. 2016;140(3):436–42.
 40. Le Saux O, Decullier E, Freyer G, Glehen O, Bakrin N. Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). *Int J Hyperthermia*. 2018;35(1):652–7.
 41. Cowan RA, O'Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. *Int J Hyperthermia*. 2017;33(5):548–53.
 42. Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. *Surg Oncol Clin N Am*.

Figures

Number at risk

IDS+HIPEC Group

121 116 75 30 4 0

IDS alone Group

76 69 25 6 0 0

Figure 1

Prpgression free survival for the ovarian cancer patients who underwent IDS with or without HIPEC with cisplatin.

Number at risk

IDS+HIPEC Group

121 118 79 33 4 0

IDS alone Group

76 71 29 7 0 0

Figure 2

Overall survival for the patients who underwent IDS with or without HIPEC with cisplatin.